Comparison of complications caused by plasma treatment with or without Alexandrite laser in the treatment of pigmented skin lesions

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240519061841N1

Enrollment

Registered

2024-06-15

Start date

2024-06-26

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Pigmented skin lesions. Condition 2: Pigmented skin lesions. Freckles Other melanin hyperpigmentation

Interventions

Intervention 1: Control group: This group will be treated only with plasma laser (Plexer, made in Italy). Intervention 2: Intervention group: This group will receive treatment starting with plasma las

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Presence of superficial skin pigment lesions Avoiding sun exposure before and after treatment

Exclusion criteria

Exclusion criteria: Use of topical treatments 2 weeks before treatment Using other invasive methods 4 weeks before treatment

Design outcomes

Primary

Measure	Time frame
Postinflammatory hyperpigmentation based on Postinflammatory severity scale (PIH severity scale). Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 28 days after the beginning. Method of measurement: Postinflammatory severity scale(PIH severity scale).;Skin infection based on Skin Infection Rating Scale (SIRS). Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 28 days after the beginning. Method of measurement: Skin Infection Rating Scale (SIRS).;Erythema based on Clinical Erythema Assessment (CEA). Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 28 days after the beginning. Method of measurement: Clinical Erythema Assessment (CEA).	—

Measure

Time frame

Postinflammatory hyperpigmentation based on Postinflammatory severity scale (PIH severity scale). Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 28 days after the beginning. Method of measurement: Postinflammatory severity scale(PIH severity scale).;Skin infection based on Skin Infection Rating Scale (SIRS). Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 28 days after the beginning. Method of measurement: Skin Infection Rating Scale (SIRS).;Erythema based on Clinical Erythema Assessment (CEA). Timepoint: At the beginning of the study (before the start of the intervention) and 7 and 28 days after the beginning. Method of measurement: Clinical Erythema Assessment (CEA).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSetareh Tehrani

Islamic Azad University

tehranirf9@yahoo.com+98 21 2200 6660

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026